Danaher Receives S.Korean FTC’s Conditional Approval for its $21.4B GE Biopharma Acquisition

 Danaher Receives S.Korean FTC’s Conditional Approval for its $21.4B GE Biopharma Acquisition

Sartorius to Acquire Danaher’s Life Science Portfolio for $750M

Shots:

  • South Korea’s FTC has approved Danaher’s $21.4 billion acquisition of GE biopharma on condition that the companies will sell eight bioprocessing product assets addressing monopoly concerns
  • The FTC’s approval follows EU’s conditional approval received in Dec 2019 after it agrees to sell five businesses to address worries about competition
  • In Feb’2019, Danaher announced the acquisition of biopharma business of GE Life Sciences in all-cash transaction making a deal value ~$21.4B

Click here to read full press release/ article | Ref: Reuters | Image: Signbox

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post